SEC ownership of BIORA THERAPEUTICS, INC.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001580063.

Comparable stake leader

Athyrium Opportunities III Co-Invest 1 LP

Disclosed value leader

Athyrium Capital Management, LP

Comparable rows

4/21

Latest evidence

30 Jun 2025

Top shareholders Insider holders Latest transactions

Parsed ownership sources: 13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder: Athyrium Opportunities III Co-Invest 1 LP
Ranking: Comparable ownership first, then disclosed value
Comparable ownership rows: 4 of 21
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder: Athyrium Opportunities III Co-Invest 1 LP
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date: 30 Jun 2025
Freshness: Most recent filing date in this holder set
Issuer CIK: 0001580063
Issuer location: San Diego, CA

Ownership snapshot

Top shareholders of BIORA THERAPEUTICS, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Athyrium Opportunities II...

Disclosed value leader

Athyrium Capital Manageme...

Comparable rows

4/21

Latest evidence

30 Jun 2025

13D/G 3/4/5 Lead comparable stake: 50% 17 rows are not safely comparable across share classes. 13D/G row: Athyrium Opportunities III Co-Invest 1 LP Showing 1-8 of 21 holder rows.

Quick read

Athyrium Opportunities III Co-Invest 1 LP leads the comparable SEC ownership view at 50%.

4 of 21 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Athyrium Opportunities III Co-Invest 1 LP's linked filing trail.

Comparable ownership Top 4

Athyrium Opportunities III Co-Inv... 50%

DAVIDSON KEMPNER CAPITAL MANAGEME... 9.9%

Margaret Ellen Taggett 6.6%

Context Capital Management, LLC 0.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 21 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Athyrium Opportunities III Co-Invest 1 LP	13D/G 3/4/5 Jeffrey A. Ferrell · Director, 10%+ Owner 13D/G 3/4/5	50%	$546,565 3,416,032 shares	$0	24 Mar 2025
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP	13D/G 13D/G	9.9%	$172,183 906,227 shares	$0	30 Jun 2025
Margaret Ellen Taggett	13D/G TAGGETT MARGARET ELLEN 13D/G	6.6%	$56,430 297,000 shares	$0	07 Apr 2025
Context Capital Management, LLC	13D/G 13D/G	0.5%	$3,304 22,025 shares	$0	30 Jun 2025
Athyrium Capital Management, LP	3/4/5 10%+ Owner 3/4/5	— mixed-class rows	$114,286,288 44,494,073 shares mixed-class rows	—	14 Jun 2021
Athyrium Opportunities Fund (A) LP	3/4/5 10%+ Owner 3/4/5	— mixed-class rows	$114,286,288 44,494,073 shares mixed-class rows	—	14 Jun 2021
Harry Stylli	3/4/5 Chairman & CEO, Director, 10%+ Owner 3/4/5	— class O/S missing	$46,523,879 14,816,522 shares	—	15 Aug 2021
Aditya P. Mohanty	3/4/5 Chief Executive Officer, Director 3/4/5	— class O/S missing	$983,968 1,468,609 shares	—	15 Aug 2024

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Sep 2025.

Buys

Insiders: 0

Sells

Insiders: 0

Net

Shares: 0

Window

Last 12 months

4 rolling buckets

Buy value Sell value

Shares: 0 Shares: 0

Window (months)	Buy value	Sell value	Net value
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-19 of 19 reporting-owner rows connected to BIORA THERAPEUTICS, INC.. Open a relationship link for the CIK-to-CIK filing trail.

Rows

Largest Forms 3/4/5 holder

Athyrium Capital Management, LP

Net 12M change

Latest report

12 Dec 2024

Name	Relationship	Holdings Value	Valuation	Report Date
Athyrium Capital Management, LP	10%+ Owner	$114,286,288	Mixed	14 Jun 2021
Athyrium Opportunities Fund (A) LP	10%+ Owner	$114,286,288	Mixed	14 Jun 2021
Harry Stylli	Chairman & CEO, Director, 10%+ Owner	$46,523,879	Mixed	15 Aug 2021
Aditya P. Mohanty	Chief Executive Officer, Director	$983,968	Mixed	15 Aug 2024
Damon Silvestry	President and General Manager, Avero	$915,307	Mixed	15 Nov 2021
Matthew T. Cooper	General Manager, Diagnostics	$420,882	Mixed	15 Nov 2021
Sami Shihabi	Chief Commercial Officer	$396,193	Mixed	15 May 2021
Eric dEsparbes	Chief Financial Officer	$385,807	Mixed	15 Aug 2024
Clarke Neumann	Officer	$311,928	Mixed	15 Aug 2024
Troy Seelye	Chief Information Officer	$187,634	Mixed	06 Aug 2021
Samuel R. Nussbaum MD	Director	$149,207	Mixed	14 Jun 2021
Bigalke John T.	Director	$149,207	Mixed	14 Jun 2021
Hutan Hashemi	Chief Compliance Officer	$89,474	Mixed	15 Feb 2022
Jill A. Howe	Director	$60,966	Mixed	05 Jun 2024
Jeffrey D. Alter	Director	$59,804	Mixed	05 Jun 2024
Brian L. Kotzin	Director	$57,292	Mixed	05 Jun 2024
Lynne Powell	Director	$57,292	Mixed	05 Jun 2024
Surbhi Sarna	Director		Mixed	03 Jan 2023
Athyrium Opportunities III Co-Invest 1 LP	Director, 10%+ Owner		Mixed	12 Dec 2024

Recent insider transactions for BIORA THERAPEUTICS, INC.

Showing up to 300 recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	SEC-reported value	SEC-reported price	Shares	Shares owned	Date	Ownership
No insider transactions were found in the last 12 months for this issuer.

^* marks a reported price that did not pass the local price check.